1.Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher MA, Haut PR,
Schultz KR, Taylor DS: Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem
Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete
Remission: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study. Biol Blood Marrow Transplant 2009; 15(12):1620-1627.
2.McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, Anasetti C,
Risler L, Sultan D, Slattery JT: Busulfan concentration and graft rejection in pediatric
patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30(3):167-173.
3.Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti
C, Bensinger WI, Fisher LD, Appelbaum FR et al: Graft-rejection and toxicity following bone marrow transplantation in relation to
busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16(1):31-42.
4.Grochow LB: Busulfan disposition: the role of therapeutic monitoring in bone marrow
transplantation induction regimens. SEMIN ONCOL 1993; 20(4):18-25.
5.Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, Savoie ML, Bahlis
NJ, Brown C, Storek J: High busulfan exposure is associated with worse outcomes in
a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biology of Blood & Marrow Transplantation Journal of the American Society for Blood
& Marrow Transplantation 2008; 14(2):220-228.
6.Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, Penza SL: Busulfan
levels are influenced by prior treatment and are associated with hepatic veno-occlusive
disease and early mortality but not with delayed complications following marrow transplantation.
BONE MARROW TRANSPL 2001; 27(11):1121.
7.Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin
LS, Devine SM, Geller RB: Association of busulfan area under the curve with veno-occlusive
disease following BMT. Bone Marrow Transplant 1996; 17(2):225-230.
8.IV Busulfex Product Information. 2015. 10.
9.Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan
M, Bredeson C et al: Personalizing Busulfan-Based Conditioning: Considerations from the American Society
for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant 2016; 22(11):1915-1925.
10.Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C: I.V. busulfan in pediatrics: a novel
dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation
recipients. BONE MARROW TRANSPL 2004; 33(10):979.
11.Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius
RG, Egberts AC, Bierings M, Kletzel M et al: Association of busulfan exposure with survival and toxicity after haemopoietic cell
transplantation in children and young adults: a multicentre, retrospective cohort
analysis. LANCET HAEMATOL 2016; 3(11):e526-e536.
12.Philippe M, Goutelle S, Guitton J, Fonrose X, Bergeron C, Girard P, Bertrand Y, Bleyzac
N: Should busulfan therapeutic range be narrowed in pediatrics|[quest]| Experience
from a large cohort of hematopoietic stem cell transplant children. Bone Marrow Transplant 2016; 13(4):72-78.
13.Maheshwari S, Kassim A, Yeh RF, Domm J, Calder C, Evans M, Manes B, Bruce K, Brown
V, Ho R: Targeted Busulfan therapy with a steady-state concentration of 600-700?ng/mL
in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.
BONE MARROW TRANSPL 2013; 49(3):366-369.
14.Michel G, Valteaucouanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, Doz F, Neven
B, Bertrand Y, Galambrun C: Weight-based strategy of dose administration in children
using intravenous busulfan: clinical and pharmacokinetic results. PEDIATR BLOOD CANCER 2011; 58(1):90-97.
15.Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R, Przepiorka D, Mezzi
K, Kletzel M, Blood P: Safety, efficacy, and pharmacokinetics of intravenous busulfan
in children undergoing allogeneic hematopoietic stem cell transplantation. PEDIATR BLOOD CANCER 2010; 54(2):291-298.
16.Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F, Mechinaud F, Galambrun
C, Neven B, Zouabi H: Prospective validation of a novel IV busulfan fixed dosing for
paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Cancer Chemotherapy & Pharmacology 2008; 61(1):113-123.
17.Bolinger AM, Zangwill AB, Slattery JT, Glidden D, Desantes K, Heyn L, Risler LJ, Bostrom
B, Cowan MJ: An evaluation of engraftment, toxicity and busulfan concentration in
children receiving bone marrow transplantation for leukemia or genetic disease. BONE MARROW TRANSPL 2000; 25(9):925-930.
18.Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM, Egeler
RM, Den HJ, Vossen JM: Intravenous busulfan in children prior to stem cell transplantation:
study of pharmacokinetics in association with early clinical outcome and toxicity.
BONE MARROW TRANSPL 2005; 35(1):17-23.
19.Jacobson P, Park JJ, Defor TE, Thrall M, Abel S, Krivit W, Peters C: Oral busulfan
pharmacokinetics and engraftment in children with Hurler syndrome and other inherited
metabolic storage diseases undergoing hematopoietic cell transplantation. BONE MARROW TRANSPL 2001; 27(8):855.
20.Faraci M, Tinelli C, Lanino E, Giardino S, Leoni M, Ferretti M, Castagnola E, Broglia
M, Silvestri AD, Martino DD: Monitoring of Busulphan Concentrations in Children Undergone
Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years. European Journal of Drug Metabolism & Pharmacokinetics 2017; 43(Suppl 2):1-9.
21.Blazar BR: Relationship of plasma pharmacokinetics of high-dose oral busulfan to the
outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20(11):915-920.
22.Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker
BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a
proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE)
group. 2008.
23.Yasuhiro O, Yoshihisa N, Yoshiyuki K, Akira K, Shunichi K, Hisato K, Yasuo H, Megumi
O, Makoto K, Tetsuya M: Prospective pharmacokinetic study of intravenous busulfan
in hematopoietic stem cell transplantation in 25 children. PEDIATR TRANSPLANT 2014; 18(3):294-301.
24.Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein
R, Vassal G: Busulfan pharmacokinetics following intravenous and oral dosing regimens
in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma
as part of the HR-NBL-1/SIOPEN trial. EUR J CANCER 2012; 48(16):3063-3072.
25.Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, Vassal
G: In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent
on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
BONE MARROW TRANSPL 2003; 32(10):979-986.
26.Bolinger AM, Zangwill AB, Slattery JT, Risler LJ, Sultan DH, Glidden DV, Norstad D,
Cowan MJ: Target dose adjustment of busulfan in pediatric patients undergoing bone
marrow transplantation. Bone Marrow Transplant 2001; 28(11):1013-1018.
27.Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle
J, Gouyette A, Hartmann O: Busulfan disposition and hepatic veno-occlusive disease
in children undergoing bone marrow transplantation. Cancer Chemotherapy & Pharmacology 1995; 37(3):247-253.
28.Wells G, Shea B, O'Connell J: The Newcastle-Ottawa Scale (NOS) for Assessing The Quality of Nonrandomised Studies
in Meta-analyses, vol. 7; 2014.
29.Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M,
Danielson M, Przepiorka D, Chan KW: Individualizing high-dose oral busulfan: prospective
dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation
for advanced hematologic malignancies. BONE MARROW TRANSPL 2000; 26(5):463.
30.Martensson T, Priftakis P, Casswall T, Ringden O, Mattsson J, Remberger M, Hassan
M, Gustafsson B: Increased risk of gastrointestinal acute GVHD following the addition
of melphalan to busulfan/cyclophosphamide conditioning. PEDIATR TRANSPLANT 2013; 17(3):285-293.
31.Mårtensson T, Priftakis P, Casswall T, Ringdén O, Mattsson J, Remberger M, Hassan
M, Gustafsson B: Increased risk of gastrointestinal acute GVHD following the addition
of melphalan to busulfan/cyclophosphamide conditioning. PEDIATR TRANSPLANT 2013; 17(3):285-293.
32.BS A, PF T, T M, D C, X W, HT T, P A, de Lima M, J G, RE C: Busulfan systemic exposure
relative to regimen-related toxicity and acute graft-versus-host disease: defining
a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biology of Blood & Marrow Transplantation Journal of the American Society for Blood
& Marrow Transplantation 2002; 8(9):477.
33.Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin
LS, Devine SM, Geller RB: Association of busulfan area under the curve with veno-occlusive
disease following BMT. Bone Marrow Transplant 1996; 17(2):225-230.
34.Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti
C, Bensinger WI, Fisher LD, Appelbaum FR: Graft-rejection and toxicity following bone
marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16(1):31-42.
35.Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin
OM: Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients
undergoing bone marrow transplantation. Cancer Chemotherapy & Pharmacology 1989; 25(1):55-61.
36.Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, Savoie ML, Bahlis
NJ, Brown C, Storek J et al: High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan
and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14(2):220-228.
37.Gibbs JP: Busulfan concentration and graft rejection in pediatric patients undergoing
hematopoietic stem cell transplantation. BONE MARROW TRANSPL 2002; 30(3):167.
38.Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, Penza SL: Busulfan
levels are influenced by prior treatment and are associated with hepatic veno-occlusive
disease and early mortality but not with delayed complications following marrow transplantation.
BONE MARROW TRANSPL 2001; 27(11):1121.
39.Slattery JT, Al E: Graft-rejection and toxicity following bone marrow transplantation
in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16(1):31-42.
40.Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, Grunebaum E, Dupuis LL:
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant
Conditioning. Biol Blood Marrow Transplant 2015; 21(8):1471-1478.
41.Corbacioglu S, Cesaro S, Faraci M, Valteaucouanet D, Gruhn B, Rovelli A, Boelens JJ,
Hewitt A, Schrum J, Schulz AS: Defibrotide for prophylaxis of hepatic veno-occlusive
disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase
3, randomised controlled trial. LANCET 2012; 379(9823):1301-1309.
42.Javid G, Antonella I, Alessia Francesca M, Aurèlie P, Laurent N, Cristiano I, Vincenzo
D, Pietro S, Marco M, Marco A: New insights into the pharmacokinetics of intravenous
busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
PEDIATR BLOOD CANCER 2015; 62(4):680-686.
43.Mcdonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED: Venocclusive disease of
the liver after bone marrow transplantation: diagnosis, incidence, and predisposing
factors. HEPATOLOGY 1984; 4(1):116-122.
44.Deleve LD, Shulman HM, Mcdonald GB: Toxic injury to hepatic sinusoids: sinusoidal
obstruction syndrome (veno-occlusive disease). SEMIN LIVER DIS 2002; 22(01):27-42.
45.Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED:
Regimen-related toxicity in patients undergoing bone marrow transplantation. Journal of Clinical Oncology Official Journal of the American Society of Clinical
Oncology 1988; 6(10):1562-1568.
46.Mcdonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman
HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone
marrow transplantation: a cohort study of 355 patients. ANN INTERN MED 1993; 118(4):255.